NCT07310355尚未招募1 期
A Phase I/II, Single-Arm, Open-Label, Dose-Escalation and Expansion Study of 68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Chengdu StarRay Therapeutics Co., Ltd0 个研究点目标入组 49 人开始时间: 2025年12月30日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 49
- 主要终点
- Incidence of adverse events [68Ga-PSMA-0057]
研究概览
简要总结
This is a single-arm, open-label, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, dosimetry, pharmacodynamics, and preliminary efficacy of Gallium [68Ga] PSMA-0057 Injection and Lutetium [177Lu] PSMA-0057 Injection as an integrated theranostic regimen in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). The study consists of a Phase I dose-escalation phase to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of 177Lu-PSMA-0057, followed by a Phase II dose-expansion phase to further evaluate preliminary antitumor efficacy and confirm safety and pharmacologic profiles. Eligible participants will receive 68Ga-PSMA-0057 for PET imaging and 177Lu-PSMA-0057 for radioligand therapy. Key objectives include characterization of safety, tolerability, pharmacokinetics, dosimetry, pharmacodynamics, and preliminary therapeutic activity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Able to communicate well with investigators, understand the study purpose and requirements, voluntarily participate, and sign written informed consent.
- •Male, ≥18 years at screening.
- •Histologically or cytologically confirmed prostate cancer (excluding neuroendocrine prostate cancer and small cell prostate cancer), previously treated with at least one novel hormonal agent and 1-2 taxane-based regimens, or deemed intolerant to taxanes.
- •Serum/plasma testosterone at castrate level (<50 ng/dL or <1.7 nmol/L).
- •Documented progressive mCRPC based on ≥1 of the following: PSA progression (two consecutive PSA rises ≥1 week apart from a minimum value of 2.0 ng/mL); soft tissue progression per PCWG3 and RECIST v1.1; or bone progression with ≥2 new lesions.
- •PSMA-positive on imaging with 68Ga-PSMA-0057 (within 3 days before treatment start) or other investigator-accepted PSMA tracers (within 6 months before treatment start), using criteria in Section 4.8.
- •At least one measurable lesion per RECIST v1.1 and/or at least one bone metastasis per PCWG
- •Estimated life expectancy ≥12 weeks.
- •ECOG performance status 0-1 at baseline.
- •Adequate organ and bone marrow function, meeting the following lab criteria:
- •Bone Marrow: Absolute Neutrophil Count (ANC) ≥1.5×109/L, Platelets (PLT) ≥100×109/L, White Blood Cell (WBC) count ≥2.5×109/L, Hemoglobin (HGB) ≥9.0 g/dL (no transfusions/growth factors within 14 days prior to screening).
- •Liver Function: Serum Total Bilirubin (T-Bil) ≤1.5 ULN (unless Gilbert's syndrome); Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) ≤3 ULN for non-liver metastasis, or ≤5 ULN for liver metastasis.
- •Renal Function: Serum creatinine ≤1.5 ULN, or estimated Glomerular Filtration Rate (eGFR) ≥50 mL/min/1.73m2 (calculated using the MDRD formula).
- •11.Serum albumin concentration ≥30 g/L 12.Toxicities from prior therapies recovered to CTCAE v5.0 Grade 0-1 (alopecia excepted).
- •13.Men with reproductive potential agree to use highly effective contraception from informed consent through 6 months after last study dose and have no plans to donate sperm.
排除标准
- •History of hypersensitivity to any study drug component or excipients, or history of specific allergic disease requiring systemic therapy, or other serious allergic reactions.
- •Prior PSMA-targeted radioligand therapy, or treatment with radionuclides such as Sr-89, Sm-153, Re-186, Re-188, Ra-223, or hemibody radiation within 6 months prior to consent.
- •Use of any investigational drug or device within 30 days before consent.
- •Systemic anticancer therapy within 28 days or 5 half-lives prior to consent (whichever is longer), including chemotherapy, radiotherapy, immunotherapy, targeted therapy, systemic immunomodulatory drugs, or antitumor traditional Chinese medicines/formulations within 2 weeks before first dose.
- •Another malignancy within the past 5 years, except for curatively treated cervical carcinoma in situ, non-melanoma skin cancers, etc.
- •Major surgery or significant traumatic injury within 4 weeks before consent.
- •Active brain metastases or CNS involvement, including untreated symptomatic lesions or those requiring radiation, surgery, or steroids within 1 month prior to screening.
- •Symptomatic spinal cord compression or clinical/imaging findings suggestive of impending cord compression.
- •Severe arterial/venous thromboembolic events within 6 months prior to screening; history of stroke; uncontrolled hypertension; decompensated heart failure (NYHA III-IV); LVEF <50%; unstable angina; clinically significant arrhythmias requiring intervention.
- •Significant acute or chronic infections, including active TB, systemic bacterial or fungal infections requiring systemic therapy.
- •Clinically significant COPD or moderate-severe chronic respiratory disease requiring systemic therapy within 6 months before first dose.
- •Uncontrolled bladder outlet obstruction or incontinence (patients managed effectively with standard measures are allowed).
- •Active autoimmune disease requiring systemic treatment within the past 2 years or likely to recur, or active peptic ulcer disease or bleeding disorders.
- •History of solid organ transplantation or allogeneic hematopoietic stem cell transplantation (corneal transplant recipients not requiring immunosuppressants may be included).
- •Syphilis, HIV infection, HCV (HCV antibody positive with detectable HCV RNA), or active HBV infection (HBsAg positive with HBV DNA ≥ULN).
- •Contraindications to PET-CT or SPECT-CT imaging, or factors deemed by the investigator to preclude adequate imaging acquisition and interpretation.
- •Any condition judged by the investigator likely to interfere with compliance or study participation, or impair the ability to give informed consent.
研究组 & 干预措施
177Lu-PSMA-0057 Treatment
Experimental
- Dose Escalation：Enroll patients with PSMA-positive progressive mCRPC who have received at least one novel endocrine therapy and 1-2 taxane-based treatment regimens, or are deemed intolerant by the investigator. Dose escalation will follow the "rolling six design" method, with two planned dose levels: 3.7 GBq and 6.0 GBq of fractionated 177Lu-PSMA-0057, administered every 6 weeks (Q6W), up to a maximum of 6 doses.
- Dose Expansion：After determining the RP2D of 177Lu-PSMA-0057, a phase II expansion will be conducted at the RP2D level (expected to expand only one dose level). Treatment will be administered every 6 weeks (Q6W), up to a maximum of 6 doses.
干预措施: 68Ga-PSMA-0057 (Drug)
177Lu-PSMA-0057 Treatment
Experimental
- Dose Escalation：Enroll patients with PSMA-positive progressive mCRPC who have received at least one novel endocrine therapy and 1-2 taxane-based treatment regimens, or are deemed intolerant by the investigator. Dose escalation will follow the "rolling six design" method, with two planned dose levels: 3.7 GBq and 6.0 GBq of fractionated 177Lu-PSMA-0057, administered every 6 weeks (Q6W), up to a maximum of 6 doses.
- Dose Expansion：After determining the RP2D of 177Lu-PSMA-0057, a phase II expansion will be conducted at the RP2D level (expected to expand only one dose level). Treatment will be administered every 6 weeks (Q6W), up to a maximum of 6 doses.
干预措施: 177Lu-PSMA-0057 (Drug)
结局指标
主要结局
Incidence of adverse events [68Ga-PSMA-0057]
时间窗: 3 days
Number of participants with adverse events as assessed by NCI-CTCAE v5.0
Incidence of adverse events [177Lu-PSMA-0057]
时间窗: up to 2 years
Number of participants with adverse events as assessed by NCI-CTCAE v5.0
Incidence of dose limiting toxicities [177Lu-PSMA-0057]
时间窗: 6 weeks
Number of participants with dose limiting toxicities
Preliminary efficacy: PSA50 response rate (Phase II)
时间窗: up to 2 years
Proportion of patients achieving ≥50% reduction in prostate-specific antigen (PSA) from baseline.
次要结局
未报告次要终点
研究者
相似试验
招募中
1 期
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaDiffuse Large B Cell Lymphoma (DLBCL)NCT07260812TCRx Therapeutics Co.Ltd18
招募中
1 期
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid TumorsColorectal CancerNon-Small Cell Lung CancerNCT07261631Novartis Pharmaceuticals180
尚未招募
1 期
A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological MalignanciesNCT07294300Qilu Pharmaceutical Co., Ltd.124
招募中
1 期
A Study of PLB-002 in Advanced Solid TumorsNCT07304128Primelink BioTherapeitics(ShenZhen) Limited100
招募中
1 期
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid TumorsBreast CancerLung CancerNCT07274852Sichuan Baili Pharmaceutical Co., Ltd.22